MedTrace Logo

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

NCT01798446 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-12-08

No results posted yet for this study

Summary

* 1\. There is no standard treatment option for non-clear cell renal cell carcinoma (RCC).
* 2\. Patients with non-clear cell RCC is strongly assumed to have benefit from anti-VEGF treatment.
* 3\. There is no trial of axitinib for non-clear cell RCC.
* 4\. Axitinib is expected to show more potent efficacy over sorafenib or sunitinib in renal cell carcinoma.

Conditions

Interventions

DRUG

Axitinib

Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Se-Hoon Lee, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-06-30
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798446 on ClinicalTrials.gov